{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 61,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/13",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.4,
        "y": 0.27
      },
      "kind": "callout",
      "text": "NXC-201 Low neurotoxicity vs. ~20-30% for others",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f05fddb-138a-43c8-85de-d767b6a8dc7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Neurotoxicity comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2c3ee6e-7e12-4b87-98d8-9bee2ee0488e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: Carvykti and Abecma FDA labels, Arcellx Corporate Presentation. Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023.. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Figures reflect cross-trial comparison and not results from a head-to head study.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81c26d66-d440-4203-852a-d20c69c3c54e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "table",
      "text": "CRS metrics table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ec0ed2d-cff0-462a-bf56-7b54ffde9f99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Is Overcoming Prolonged CRS and Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "067acb7a-6c3f-493c-b4e5-df4056325075",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "3121a669-3cb1-4c20-bde8-29c0b025c8d1",
      "evidence": "Direct comparison of NXC-201 against three competitors across safety metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}